alanine has been researched along with plitidepsin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 2 (100.00) | 2.80 |
Authors | Studies |
---|---|
Avilés, P; Batra, J; Bouhaddou, M; Coughlan, L; Dejosez, M; Fabius, JM; García-Sastre, A; Guillén, MJ; Jangra, S; Kehrer, T; Krogan, NJ; Losada, A; Martinez-Romero, C; Miorin, L; Moreno, E; Obernier, K; Rathnasinghe, R; Rojc, A; Rosales, R; Schotsaert, M; Shokat, KM; Uccellini, MB; Vignuzzi, M; White, KM; Yildiz, S; Zwaka, T | 1 |
Ledford, H | 1 |
2 other study(ies) available for alanine and plitidepsin
Article | Year |
---|---|
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Coronavirus Nucleocapsid Proteins; COVID-19; COVID-19 Drug Treatment; Depsipeptides; Drug Evaluation, Preclinical; Female; HEK293 Cells; Humans; Lung; Mice, Inbred C57BL; Mutation; Peptide Elongation Factor 1; Peptides, Cyclic; Phosphoproteins; RNA, Viral; SARS-CoV-2; Virus Replication | 2021 |
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Cytidine; Depsipeptides; Dexamethasone; Drug Combinations; Drug Repositioning; Drug Synergism; Esters; Guanidines; Hospitalization; Host-Pathogen Interactions; Humans; Hydroxylamines; Internationality; Lactams; Leucine; Mice; National Institutes of Health (U.S.); Nitriles; Peptide Elongation Factor 1; Peptides, Cyclic; Proline; Protease Inhibitors; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Serine Endopeptidases; Sodium-Glucose Transporter 2 Inhibitors; United States; Virus Replication | 2022 |